Gene Therapy Allowing Heart to Grow New Blood Vessels Supported by Early Data
Researchers are eyeing catheter-based delivery for people with refractory angina
Stay updated with breaking news from Neovasc Reducer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers are eyeing catheter-based delivery for people with refractory angina
A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.
In this placebo-controlled study, CMR imaging disappointed a little, but the device did make patients feel better.
After ORBITA-COSMIC, Reducer device's mechanism of benefit remains unknown
SANTA CLARA, Calif., Dec. 20, 2023 -- Shockwave Medical, Inc. , a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease,...